PDCD1 and neoplasm: Notably, the combination of chemotherapeutics with BMS-1166 modulated these effects in a drug-dependent manner, suggesting that BMS-1166 may enhance or counteract chemotherapy-induced changes in PD-1/PD-L1 and resistance protein expression within the tumor immune microenvironment (Figure 10A).